Oncology News | pharmaphorum

News

Final obstacles in front of Pfizer, Seagen merger fall

Pfizer is expecting to close its $43 billion acquisition of antibody-drug conjugate (ADC) pioneer Seagen tomorrow, after receiving all the required regulatory approvals fo

News

Digitised pathology resource will speed HIV cancer R&D

A collection of clinical specimens that has been gathered from people living with HIV for almost 30 years has been given a digital makeover with the help of computational

News

BMS bolts on SystImmune bispecific ADC in $8.4bn deal

The litany of big-ticket deals involving antibody-drug conjugates shows no sign of ending.

News

ASH: Sanofi’s Sarclisa carves out a multiple myeloma niche

Sanofi’s anti-CD38 antibody Sarclisa has struggled to make headway against Genmab and Johnson & Johnson’s rival Darzalex since it was first approved for multiple myelo

News

MSD, Moderna take mRNA jab into phase 3 for lung cancer

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non

News

Regeneron bids to join the BCMA bispecific camp

Regeneron has moved closer to a regulatory filing for its BCMAxCD3 bispecific antibody linvoseltamab, the first of a series of bispecifics that is spearheading its oncolog

Final obstacles in front of Pfizer, Seagen merger fall

Digitised pathology resource will speed HIV cancer R&D

BMS bolts on SystImmune bispecific ADC in $8.4bn deal

ASH: Sanofi’s Sarclisa carves out a multiple myeloma niche

MSD, Moderna take mRNA jab into phase 3 for lung cancer

Regeneron bids to join the BCMA bispecific camp

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

News

Editor's Picks